#Biotechnology #Epilepsy #ConferenceCall
www.benzinga.com
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - Bright Minds Biosciences (NASDAQ:DRUG)
- Conference Call and Live Webcast at 8AM ET -
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc.
